Assessment of the Hemodynamic Effects of PEEP According to Alveolar Recruitment During the ARDS

August 30, 2022 updated by: Xavier Monnet, Bicetre Hospital
The corner stone of the treatment of ARDS is mechanical ventilation with high levels of positive end-expiratory pressure, also called PEEP. A high level of PEEP is recommended and frequently used. But PEEP can lower cardiac output and contribute to circulatory failure during mechanical ventilation. Nevertheless, in theory, the PEEP-induced pulmonary vascular resistance (PVR) increase could depend on the level of alveolar recruitment, but it has never been proven. Thus, the aim of this study is to determine the relation between the high-PEEP induced PVR and the alveolar recruitment or overdistension.

Study Overview

Detailed Description

During acute respiratory distress syndrome (ARDS) the application of positive end-expiratory pressure (PEEP) prevents expiratory alveolar collapse. However, it can induce a predominant recruitment effect or, on the contrary, alveolar overdistension. The recruitment/overdistension ratio can be easily assessed using R/I ratio (or recruitment-to-inflation ratio). However, PEEP is likely to lower cardiac output and contribute to the cardiovascular failure that often occurs in patients with ARDS. Among its hemodynamic effects, PEEP is likely to increase pulmonary vascular resistance and, thus, right ventricular afterload. In theory, this effect should only occur if PEEP over-distends the lung volume, compressing the "extra-alveolar" vessels and increasing their resistance. However, this different effect of PEEP on pulmonary vascular resistance depending on the degree of recruitment or overdistension has never been demonstrated during ARDS in humans.

We retrospectively studied data collected from patients with ARDS, monitored by pulmonary artery catheter (PAC), to eventually find a correlation between the high PEEP-induced PVR increase and recruitement/overdistension profile.

Study Type

Observational

Enrollment (Anticipated)

34

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ile-de-France
      • Le Kremlin-Bicêtre, Ile-de-France, France, 94270
        • Recruiting
        • Bicetre Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Mechanically ventilated patients over the age of 18, exhibiting ARDS and with a PAC-monitoring already in place.

Description

Inclusion Criteria:

  • ARDS diagnosed
  • Invasive mechanical ventilation
  • Pulmonary artery catheter already in place
  • Esophagal pressure measure

Exclusion Criteria:

  • Pregnancy
  • Prone position at inclusion
  • Legal protection measures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between PVR and recruitment-to-inflation ratio
Time Frame: Up to hospital discharge (maximum : day 60)
PVR collected at two levels of PEEP and the R/I ratio to assess a relationship between the two variables
Up to hospital discharge (maximum : day 60)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relationship between the R/I ratio and blood gas analysis
Time Frame: Up to hospital discharge (maximum : day 60)
Data collected from the daily blood samples, to assess a relationship between R/I and arterial oxygen pressure
Up to hospital discharge (maximum : day 60)
Relationship between the R/I ratio and respiratory system compliance
Time Frame: Up to hospital discharge (maximum : day 60)
Ventilatory parameters collected at two levels of PEEP and R/I collected every day to assess a correlation between R/I and lung compliance
Up to hospital discharge (maximum : day 60)
Relationship between right ventricle size and R/I ratio
Time Frame: Up to hospital discharge (maximum : day 60)
Echocardiographic data collected at two levels of PEEP and R/I collected every day to assess a relationship between R/I and changes in RV surface.
Up to hospital discharge (maximum : day 60)
Relationship between PVR change and Transpulmonary gradient (TPG) according to R/I
Time Frame: Up to hospital discharge (maximum : day 60)
Data collected from PAC and R/I measure every day to assess the relationship between R/I and TPG at two levels of PEEP.
Up to hospital discharge (maximum : day 60)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2022

Primary Completion (Anticipated)

September 1, 2022

Study Completion (Anticipated)

November 1, 2022

Study Registration Dates

First Submitted

August 30, 2022

First Submitted That Met QC Criteria

August 30, 2022

First Posted (Actual)

September 1, 2022

Study Record Updates

Last Update Posted (Actual)

September 1, 2022

Last Update Submitted That Met QC Criteria

August 30, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2022-A00058-35

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ARDS, Human

Clinical Trials on Pulmonary artery catheter

3
Subscribe